Previous Article | Next Article 
Journal of Virology, April 1999, p. 2675-2681, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mutational Analysis of the Human
Immunodeficiency Virus Type 1 Vif Protein
James H. M.
Simon,1
Ann M.
Sheehy,2
Elise A.
Carpenter,2
Ron A. M.
Fouchier,2 and
Michael H.
Malim1,2,3,*
Howard Hughes Medical
Institute2 and Departments of
Microbiology1 and
Medicine,3 University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6148
Received 30 July 1998/Accepted 9 December 1998
 |
ABSTRACT |
Lentivirus Vif proteins are potent regulators of virus infectivity.
However, relatively little is known about the functional domains,
peptide motifs, or residues of any Vif protein. In this report, we
present the first extensive mutagenesis analysis of the 192-amino-acid
human immunodeficiency virus type 1 (HIV-1) Vif protein. A large number
of scanning missense (mostly alanine substitution) and deletion
mutations were introduced into the HIV-1HXB3
vif gene, and the resulting proteins were evaluated for the
induction of virus infectivity as well as subcellular localization. The
results show that amino acids dispersed throughout Vif's linear
sequence are important for function. However, because many of the
inactive proteins also appear to be mislocalized, we suggest that many
of them may actually be misfolded rather lacking an intracellular
targeting signal. Interestingly, disruptions within an internal region
spanning residues 114 to 146 give rise to mutant proteins that either
retain function or are inactive but are not substantially mislocalized.
We therefore speculate that this region, which harbors two essential
cysteine residues and one essential serine residue, may contain aspects
of a putative Vif effector domain.
 |
INTRODUCTION |
One of the features that
distinguishes lentiviruses from prototypic oncoretroviruses is their
marked genetic complexity. For example, human immunodeficiency virus
type 1 (HIV-1) encodes six accessory/regulatory genes in addition to
the structural and enzymatic gag, pol, and
env genes that are present in all replication-competent retroviruses. The functions of three of these genes, tat,
rev, and vpu, are relatively well established,
while those of vif, vpr, and nef
remain rather less evident (5, 7).
The consensus model for the function of Vif (viral infectivity factor)
is that it acts at a late stage of the virus life cycle, such as
assembly or budding, to enhance the infectivity of progeny virions 10- to 100-fold (1, 3, 9, 10, 22, 26, 31). Although the point at
which vif-deficient (
vif) infections are inhibited remains ill defined, current evidence is consistent with the
postentry nucleoprotein complexes (often called preintegration complexes) of
vif viruses being unstable and therefore
subject to premature dissolution prior to provirus formation (12,
26). To date, however, the molecular events that take place in
virus-producing cells and which predetermine this defect have remained
elusive. In particular, biochemical analyses of wild-type and
vif virions, and their respective producer cells, have
failed to reveal any consensus differences in the virion incorporation
or processing of the Gag, Pol, and Env proteins (3, 9, 20,
31). Furthermore, even though the Vif protein itself is packaged
into virions (4, 9, 14, 15), this appears to be relatively
inefficient, correlative with cellular expression levels, and not
required for viral infectivity (4, 27).
Consistent with the model that Vif provides a critical function during
virus production, confocal microscopy analyses of HIV-1- and feline
immunodeficiency virus-infected cells have shown that there is
substantial colocalization between Gag and Vif (24). Furthermore, we have recently demonstrated that p55Gag and
Vif derived from lysates of HIV-1-infected cells cofractionate in
continuous density gradients in the presence of nonionic detergent (23). Importantly, however, coimmunoprecipitation
experiments failed to provide evidence to support the idea that Vif and
Gag stably interact with each other (23), a finding that
appears to contrast with one recent report (2). Based on
these observations, we have speculated that Vif and the Gag precursor
are independently targeted to a region of the cell where aspects of
virion assembly can be regulated. Implicit in this model is the notion
that Vif interacts with cellular components in a manner that is
essential for its biological activity. Indeed, this hypothesis is
supported by other data which suggest that Vif function is subject to a cell species-specific restriction (28) and that Vif acts by suppressing an innate cellular activity which inhibits the infectivity of progeny virions (25).
To understand the function of a given protein at the molecular level,
an appreciation of functional domains, motifs, and residues can be of
tremendous help. Somewhat surprisingly, an extensive structure-function
analysis of the HIV-1 Vif protein has not yet been described. Moreover,
the lack of any obvious sequence similarity between Vif and any
database entry has not allowed one to predict a precise function for
Vif or to identify possible functional motifs. Alignment of lentivirus
Vif proteins derived from primate and nonprimate hosts has led to the
recognition of a single conserved motif
(S/T)LQ(F/Y/R)LA
(18)
that, at least for HIV-1, is important for biological
function (33). In the work presented here, we have
characterized a large panel of substitution and deletion mutants of the
HIV-1 Vif protein by using both a single-cycle functional assay for
virus infectivity and biochemical fractionation of virus-producing T
cells. Our results show that the conserved domain of Vif is important
for the function not only of HIV-1 Vif but also of the Vif protein of
simian immunodeficiency virus isolated from rhesus macaques
(SIVMAC). We also find that amino acid substitutions
distributed throughout HIV-1 Vif are capable of disrupting function
and, in many cases, normal localization. Furthermore, we find that Vif
does not appear to tolerate the deletion of any region of five or six
amino acids except in its carboxy terminus. Based on these findings, we
have concluded that HIV-1 Vif cannot be organized into a number of
discrete, independently acting functional domains. In particular, it
appears that Vif may be folded such that the residues distributed
throughout its sequence participate in correct subcellular localization.
 |
MATERIALS AND METHODS |
Expression vectors.
The wild-type and
vif-deficient HIV-1 proviral expression vectors pIIIB and
pIIIB/
vif, as well as the HIV-1 Vif expression and
control vectors pgVif and pg
Vif, have been described elsewhere (28, 29). Missense and deletion mutants of HIV-1 Vif were generated in pgVif by PCR-mediated site-directed mutagenesis, and the
integrity of the resulting vif genes was confirmed by automated sequencing. Selected mutated derivatives of HIV-1
vif were rebuilt into proviral clones by replacing the
NdeI fragment of pIIIB (positions 5127 to 6404) with that
from the pgVif mutant vector. Mutants of SIVMAC Vif were
similarly generated in the T7 epitope-tagged vector
pgVif:T7SIVMAC (28). The pHIT/G vector expresses
the vesicular stomatitis virus G envelope glycoprotein (8).
Functional analysis of Vif mutants.
The biological
activities of mutant Vif proteins were determined by using a
single-cycle infectivity assay based on the induced expression of the
viral transcription trans activator Tat (9, 26).
H9 cells were electroporated with pIIIB/
vif together with pg
Vif (negative control), pgVif (positive control), or a mutated version of pgVif and then incubated at 37°C for 20 h in fresh medium. The cultures were then transferred to centrifuge tubes and
centrifuged at 500 × g for 5 min. The cell pellets
were washed in phosphate-buffered saline (PBS) and lysed for subsequent
Western analysis, while the virus-containing supernatants were filtered through 0.45-µm-pore-size filters and quantitated for
p24Gag by enzyme-linked immunosorbent assay; 5 × 105 C8166/HIV-CAT indicator cells were then
challenged with normalized quantities of virus. After 24 h, the
cells were lysed in 100 mM Tris-HCl (pH 7.8)-0.5% (vol/vol) Triton
X-100 (TX-100) for the determination of chloramphenicol
acetyltransferase (CAT) activity.
Western analyses and antibodies.
Cell fractions, whole-cell
lysates, or immunoprecipitates were resolved by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis and electrophoretically
transferred to nitrocellulose. The filters were initially hybridized
with a mouse monoclonal antibody raised against HIV-1 Vif (319)
(29) or HIV-1 p24Gag/CA (p24-3) (24),
and bound antibodies were detected by using appropriate horseradish
peroxidase-conjugated secondary antibodies raised against mouse or
rabbit immunoglobulins, enhanced chemiluminescence, and autoradiography.
Transient infection of H9 cells with HIV-1.
Cells were
transiently infected with HIV-1 carrying a wild-type or mutated
vif gene as previously described (23).
Specifically, initial high-titer stocks of pseudotyped viruses were
transiently generated by transfection of 293T monolayers with the
relevant pIIIB-based proviral vector and pHIT/G (28). After
24 h, virus-containing supernatants were harvested, clarified by
centrifugation at 500 × g for 5 min, filtered through
0.45-µm-pore-size filters, and used to infect 107 H9
cells. After 4 h, the cells were washed in PBS three times to
remove input viruses and incubated in fresh medium at 37°C for a
further 20 h. The cells were then washed two additional times and
incubated in fresh medium for 24 h. At this point, the cultures
were centrifuged at 500 × g for 5 min, and the cells were washed in PBS and lysed in preparation for fractionation.
Subcellular fractionation of virus-expressing cells.
Fractionations were performed as described elsewhere (23).
Briefly, cells were lysed by incubation in PBS-1% TX-100 for 10 min
on ice. Nuclei were then pelleted by centrifugation at 1,000 × g for 10 min at 4°C and lysed in radioimmunoprecipitation assay (RIPA) buffer (0.1% SDS, 1% TX-100, 1% sodium deoxycholate, 150 mM NaCl, 10 mM Tris-HCl [pH 7.5], 1 mM EDTA). The TX-100-soluble and -insoluble fractions of the postnuclear supernatants were separated
by centrifugation at 100,000 × g for 60 min in a TLA 100.2 rotor. The resulting pellet was redissolved in 1× RIPA buffer (TX-100-insoluble fraction), and the soluble supernatants were adjusted
to 1× RIPA buffer. Importantly, all three fractions were made up to
the same final volume.
Alternatively, the postnuclear supernatants were subjected to density
gradient centrifugation at 150,000 × g for 2 h in
20 to 60% continuous sucrose gradients. Following collection as 10 1-ml samples, the fractions were diluted fourfold with cold PBS and
centrifuged at 100,000 × g as described above, and the
pellets were resuspended in gel loading buffer. Alternatively, an
aliquot of each fraction was adjusted to 1× RIPA and subjected to
immunoprecipitation using a rabbit polyclonal Vif-specific antiserum
and protein A-conjugated agarose beads.
 |
RESULTS |
Generation and functional analysis of mutant HIV-1 Vif
proteins.
A scanning mutagenesis analysis of the HIV-1 Vif protein
has not been reported. As an approach to identify critical regions of
this protein, and thereby to gain further insight into its mechanism of
action, a series of amino acid substitution and in-frame deletion
mutations were introduced into the vif gene of
HIV-1HXB3 (Tables 1 and
2). Residues that have previously been
shown to be critical for function (16, 33), that are
conserved among primate lentivirus Vif proteins (18), or
that are well conserved between diverse HIV-1 isolates (32)
were chosen as the primary sites for disruption. In many cases, a
unique SacII restriction site was introduced into the
vif gene of the pgVif expression vector such that two or
three residues were replaced with alanines. In addition, the use of a
single restriction site facilitated the subsequent construction of a
series of in-frame deletion mutations.
To test the various mutant Vif proteins for function, nonpermissive H9
cells (the production of infectious virions from these cells requires
Vif) were cotransfected with each of the pgVif-derived vectors and the
vif-deficient provirus expression vector
pIIIB/
vif. Importantly, this two-plasmid strategy allowed
us to discount any indirect effects on viral infectivity that might
have resulted from mutations in vif influencing proviral
sequences with other functions, such as the overlapping pol
and vpr genes. Resultant viruses were then harvested at
20 h, normalized according to p24Gag content, and used
in challenges of C8166/HIV-CAT indicator cells. The positive
and negative control viruses were produced by cotransfection of
pIIIB/
vif with pgVif and pg
Vif, respectively; of note,
we found that the infectivity of virus produced by cotransfection of
pIIIB/
vif with pgVif was identical to that of wild-type
(Vif-expressing) virus produced by cotransfection of pIIIB and a
negative control vector (data not shown).
Since the induction of infectivity of HIV-1/
vif by
wild-type Vif ranged from 5- to 20-fold over the negative control in
different experiments, and because we wished to compare several
different data sets with each other, we assigned arbitrary infectivity
values of 1 and 100 to the negative (pIIIB/
vif plus
pg
Vif) and positive (pIIIB/
vif plus pgVif) controls,
respectively. Tables 1 and 2 show the relative activities of each of
the mutant Vif proteins, as an average of several separate experiments.
The results demonstrate that missense mutations distributed throughout
the linear sequence of HIV-1 Vif can disrupt function (summarized in
Fig. 1) and that deletion mutations at
all tested locations, except in the carboxy-terminal region, can
abrogate function (Table 2). Importantly, Western analyses of
whole-cell lysates derived from these (cotransfected) virus-producing
H9 cultures confirmed that all mutant proteins were expressed and that
their relative levels of accumulation did not correlate with activity
(data not shown).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
Site-directed mutagenesis of the HIV-1 Vif protein. The
primary amino acid sequence of HIV-1HXB3 Vif is shown
together with the missense mutations that were introduced (boxes for
multiple substitutions and ovals for single substitutions). Black
backgound, 1 to 15% activity compared to wild-type Vif; gray
background, 15 to 50% activity; white background, greater than 50%
activity (Table 1). In the case of residues 161 to 163, substitution of
all three in M14 severely inhibited function whereas changes of the
individual amino acids were relatively inconsequential.
|
|
One attribute that nonfunctional mutant proteins may display is the
ability to suppress the activity of their cognate wild-type protein.
Indeed, such dominant negative (also termed trans-dominant) mutants have previously been described for the HIV-1
accessory/regulatory proteins Rev and Tat (17, 21). To
determine whether any of our mutant Vif proteins that had less than
15% of wild-type activity had a dominant negative phenotype, we tested
the infectivities of viruses derived by cotransfection of H9 cells with
pIIIB/
vif, wild-type pgVif, and each of the mutated pgVif
vectors (1 to 5 ratio of wild type to mutated vectors). All viruses
produced in this manner had infectivities that were indistinguishable
from that of virus produced in the presence of the wild-type protein alone (data not shown). As an additional test of potential dominant negative behavior, the various inactive Vif proteins were also coexpressed in permissive CEM-SS cells (infectious virion production by
these cells does not require Vif) together with
HIV-1/
vif; as with the H9 studies, no inhibition of viral
infectivity was observed for any of these proteins (data not shown).
Subcellular localization of nonfunctional mutants of Vif.
We
have previously shown that Vif and p55Gag are associated
with cytoplasmic complexes that are resistant to solubilization with nonionic detergents (23). Consistent with immunofluorescence studies which demonstrated that Vif and Gag colocalize in the cytoplasm
of virally infected cells (24), these Vif- and
Gag-containing complexes cofractionate in continuous sucrose density
gradients (23). Furthermore, it was also noted that Vif and
Gag are localized to these complexes independent of each other, most
likely via protein-protein interactions. To gain a better appreciation
of the molecular bases for some of the loss-of-function phenotypes observed, we decided to determine the patterns of subcellular localization for a subset of our mutant Vif proteins by using a
procedure which yields a nuclear sample, as well as TX-100-soluble and
-insoluble cytoplasmic fractions (Fig.
2). Hypothetical outcomes for such
experiments include the identification of (i) mutations which alter
localization and would potentially have affected an intracellular
targeting signal or (ii) mutations which do not influence localization
and would potentially have disrupted effector function. In addition to
analyzing various missense mutants, and since the carboxy terminus has
previously been implicated as a membrane targeting signal in HIV-1 Vif
(11, 13), we also evaluated the
12,
13, and
14
deletion mutants (Table 2). Because of the very poor transfection
efficiencies that can be attained with H9 cells and the significant
degree of cell death imparted by electroporation, it proved to be
infeasible to perform fractionation studies using cells transiently
cotransfected with pIIIB/
vif- and pgVif-derived vectors
(data not shown). We circumvented this problem by introducing the
pertinent mutant vif alleles (none of which affected
pol or vpr) into pIIIB; this made it possible to
generate initial high-titer virus stocks in 293T cells (a permissive cell line) and then to use them to infect H9 cells at high efficiency and render them virus producers amenable to these biochemical studies.
Importantly, this strategy also provided an internal standard for
fractionation in that the H9 cultures were also expressing Gag.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 2.
Subcellular localization of Vif and Gag in H9 cells
infected with wild-type (WT) or vif mutant viruses. Cells
were infected with virus, maintained for 20 h, and separated into
nuclear (N), TX-100-insoluble (I), and TX-100-soluble (S) fractions.
All samples were analyzed by Western blotting using Gag-specific (upper
panels) or Vif-specific (lower panels) monoclonal antibodies.
Representative gels for each of the four different fractionation
profiles are shown together with the Vif proteins that localized with
each of those patterns and their relative activities (Table 1); these
gels were obtained with M10, M23, M32, and wild-type Vif. Note that the
Gag proteins (in particular, p55Gag and CA) fractionated
identically regardless of which Vif protein was coexpressed.
|
|
For all of the mutant viruses tested, the fractionation patterns of
p55Gag and its processed products were identical to those
of wild-type virus (Fig. 2, upper panels; and data not shown). This was
to be expected since we have previously shown that coexpression of Vif
with Gag does not appear to influence the subcellular localization of
Gag (23). When the filters were reprobed with a Vif-specific antibody, four basic fractionation patterns were observed (Fig. 2,
lower panels; and data not shown): primary localization to the
TX-100-insoluble fraction (right-hand panel), approximately equal
division between the soluble and insoluble fractions (center-right panel), predominant localization to the soluble fraction (center-left panel), or almost entire localization to this fraction (left-hand panel). In no cases, however, did we find substantial fractionation with the nuclear pellets.
Wild-type Vif, as described previously, localized mostly to the
TX-100-insoluble fraction. Indeed, all functional and partially functional mutants that were examined displayed either this pattern of
localization or a relatively even division between this fraction and
the TX-100-soluble fraction. In other words, none of the biologically active Vif proteins localized predominantly to the detergent-soluble fraction; we have interpreted this observation as suggesting that targeting to the detergent-insoluble fraction is important for Vif
function. In contrast, we identified nonfunctional Vif proteins that
fractionated with each of the four different patterns. Because the
amino acid alterations that prevent accumulation in the
TX-100-insoluble fraction are distributed throughout Vif's primary
sequence, it appears that HIV-1 Vif's localization signal is
conformationally sensitive and may be formed by noncontiguous residues
derived from more than one region of the protein. With respect to the proline-rich element at residues 161 to 164 (Fig. 1), even though the
M14 and M41 proteins were severely mislocalized, the finding that the
more extensive
13 mutant (deletion of residues 147 to 163) still
localized like wild-type Vif suggests that this region does not mediate
targeting to the detergent-insoluble fraction.
Having constructed a number of proviruses that carry disrupted
vif genes, we also wished to determine whether the
phenotypes of a selection of the mutant Vif proteins were maintained in
the context of spreading virus infections. Virus stocks derived from transfected 293T cells were used to challenge nonpermissive H9 cells
and permissive CEM-SS cells, and virus production was monitored over
time as the accumulation of p24Gag in the culture
supernatants. Consistent with the single-cycle cotransfection assays
(Table 1), M21, M23, M10, and M29 each failed to support spreading
infections in H9 cells whereas M32 appeared to be fully functional; in
contrast, all five viruses replicated efficiently in CEM-SS cells (data
not shown).
Fractionation using continuous sucrose density gradients.
In
addition to colocalizing in TX-100-insoluble cytoplasmic complexes, Vif
and p55Gag also cosediment in sucrose density gradients
(23). Accordingly, and as a more rigorous examination of the
subcellular localization of certain mutant Vif proteins, the
postnuclear supernatants of H9 cells infected with HIV-1 expressing
wild-type Vif or the inactive M21, M5, M29,
12, or
13 proteins
were fractionated on 20 to 60% sucrose gradients. Following
fractionation, all samples were subjected to centrifugation at
100,000 × g for 60 min to pellet complexes or adjusted
to 1× RIPA buffer, and the Vif proteins were immunoprecipitated with a
rabbit polyclonal antiserum. All samples were then analyzed by Western
blotting using Vif- or Gag-specific monoclonal antibodies (Fig.
3).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Sedimentation of Vif and Gag in continuous sucrose
density gradients. Postnuclear supernatants of H9 cells prepared as for
Fig. 2 were loaded onto 20 to 60% (wt/vol) sucrose gradients,
centrifuged at 150,000 × g for 2 h, and
fractionated into 1-ml samples. Each fraction was either subjected to
high-speed centrifugation at 100,000 × g for 60 min to
pellet complexes (A, B, D, and E) or adjusted to 1× RIPA and the
wild-type and M21 Vif proteins were immunoprecipitated with a
Vif-specific antiserum raised in rabbit (C and F). All samples were
analyzed by Western blotting as for Fig. 2. The identities of the
detected proteins are indicated to the right of each panel.
|
|
As previously demonstrated (23) and consistent with the
results obtained with the three-fraction approach (Fig. 2), the localization of Gag was unaffected by the presence of any Vif protein
and, therefore, peaked in fractions 2 to 5 of these gradients (Fig. 3A
and D and data not shown). Importantly, these same fractions also
contained the majority of the wild type, M5, M29,
12 and
13
proteins that were recoverable by either high speed centrifugation (Fig. 3B and data not shown) or immunoprecipitation (Fig. 3C and data
not shown). That low levels of these proteins were also detected at the
tops of the gradients by immunoprecipitation (Fig. 3C) was to be
expected since small proportions of these proteins are always present
in TX-100-soluble forms (Fig. 2). The analysis of the M21-containing
gradient confirmed the mislocalization phenotype of this protein.
Specifically, even though the pelleting of fractions revealed a peak of
M21 that coincided with Gag (Fig. 3D and E), immunoprecipitation
revealed not only that this peak represented a small proportion of the
total amount of M21 that was present but also that the majority of this
protein was found at the top of the gradient (Fig. 3F). Based on these
results, we have concluded that the ability of any given Vif protein to
localize to TX-100-insoluble complexes correlates with
p55Gag colocalization in density gradients.
Functional analysis of mutated SIVMAC Vif
proteins.
On the basis of the above results, we decided to analyze
in greater detail the functional importance of two regions of Vif, namely, the 144SLQ and 161PPXP motifs of the
HIV-1 protein. The 144SLQ region is well conserved among
divergent lentivirus Vif proteins (18) (Fig.
4A) and yields inactive mutant proteins
that localize like wild-type Vif when disrupted in the HIV-1 background
(mutants M29 and
12) (Tables 1 and 2). The proline-rich motif at
positions 161 to 164 is conserved among divergent HIV-1 isolates (Fig.
4B), bears some similarity to other proline-rich sequences that mediate protein-protein interactions (30), and can also yield
nonfunctional proteins when mutated (M14 and M41) (Table 1). Even
though this precise motif is not present in other lentivirus Vif
proteins, the HIV-2 and SIVMAC proteins do harbor two
closely positioned prolines toward their carboxy termini (Fig. 4B).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
Sequence alignments of the serine-leucine-glutamine
(SLQ) (A) and proline-rich elements (B) of HIV-1 Vif and other
lentivirus Vif proteins. The positions at which alanine substitutions
were introduced into HIV-1 Vif (A, M29; B, M14 and M41) or
SIVMAC Vif (A, SM1; B, SM2) are indicated.
SIVAGM/TAN, SIV isolated from a tantalus African green
monkey; FIV, feline immunodeficiency virus. Consensus sequences for the
proline-rich elements of the A, B, D, and O clades of HIV-1 are also
shown.
|
|
To evaluate the significance of these two elements in the context of
the SIVMAC Vif protein, we constructed the SM1 and SM2 alanine substitution mutant forms of the pgVif:T7SIVMAC
vector. The biological activity of each protein was determined by
cotransfection of H9 cells with pIIIB/
vif and infectivity
measurements using C8166/HIV-CAT indicator cells (Fig.
5); the pgVif:T7HIV-1 and pgVif:T7SIVMAC vectors served as positive controls, and
pg
Vif was used as the negative control (28). The SM1
mutant protein displayed a level of activity that was less than 10% of
that of either of the wild-type proteins, whereas the SM2 protein
clearly retained wild-type levels of activity. It therefore appears
that the SLQ motif of Vif participates in the conserved function of this family of proteins, whereas the carboxy-terminal proline-rich elements of primate lentiviral Vif proteins do not. Given that the M29
and
12 mutant variants of HIV-1 Vif both localize identically to the
wild-type protein in infected cells (Fig. 2 and 3), we speculate that
the SLQ motif may contribute directly to the effector function of Vif.

View larger version (0K):
[in this window]
[in a new window]
|
FIG. 5.
Functional analysis of the SLQ and proline-rich
sequences in SIVMAC Vif. The indicated wild-type and
mutant Vif expression vectors were cotransfected into H9 cells with
pIIIB/ vif, and the resultant viruses were tested for
infectivity in C8166/HIV-CAT indicator cells (Table 1).
|
|
 |
DISCUSSION |
In an effort to identify functional residues and motifs in the Vif
protein of HIV-1, we have generated a number of scanning alanine
missense and in-frame deletion mutant proteins. These were all
evaluated for function in a trans-activation assay in which
a vif-deficient mutant of HIV-1 served as the substrate and
infectivities were measured within 24 h of viral challenge. A
number of the alanine substitution mutants displayed substantial losses
of activity (Table 1 and Fig. 1), whereas all of the deletion mutants,
with the exception of carboxy-terminal truncations, were essentially
inactive (Table 2). Based on these results, we are currently unable to
organize HIV-1 Vif into a straightforward domain structure.
As noted earlier, relatively few mutations in HIV-1 vif have
been described. Of those that have been reported, the critical roles
played by the cysteine residues at positions 114 and 133 as well as the
serine at position 144 are confirmed by our results (16, 33)
(Fig. 1); indeed, the importance of 144S is further
underscored by the finding that the analogous region in the Vif protein
of SIVMAC is essential for activity (Fig. 4 and 5). It has
also been reported that the combined action of a number of positively
charged amino acids toward Vif's carboxy terminus contributes to
function (2, 11, 13). Although the substitution of the
lysines at positions 157 and 160 had no effect on activity (Fig. 1), we
did find that the deletion of residues 169 to 190, which removes five
basic amino acids, resulted in an ~70% loss of function (Table 2).
Interestingly, a carboxy-terminal truncation of Vif to residue 173 (a
deletion of residues 174 to 192) has been shown to have no effect on
virus replication in nonpermissive cells when introduced into an
infectious molecular clone (19). Although this might appear
to be inconsistent with the results of single-cycle studies which have
implied that the carboxy terminus participates in Vif function
(11, 13) (Table 2), these experimental configurations are
not necessarily directly comparable. Thus, the role(s) of positively
charged residues in this region remains an open question.
In addition to determining function in terms of the induction of
infectivity, we assessed the subcellular localization patterns of many
mutant proteins in H9 cells in the presence of all other viral proteins
(Fig. 2 and 3). Many of the inactive mutants that were examined
mislocalized such that significant amounts of those proteins were
present in the TX-100-soluble fraction of a postnuclear supernatant
(Fig. 2). The mutations that resulted in mislocalization were scattered
throughout Vif's primary sequence, which suggests that many may have
disrupted secondary or tertiary structure as opposed to a specific
targeting signal. In contrast, the functional mutants that were tested
all localized substantially to the TX-100-insoluble fraction (Fig. 2),
a finding which suggests that targeting to this region(s) of the cell
may be important for Vif function. In summary, however, we feel that a
better understanding of these results requires detailed information on
the tertiary structure of Vif.
As discussed, the function of Vif during the late stages of the HIV-1
life cycle remains ill defined at the molecular level, though recent
experiments are consistent with the notion that Vif acts to suppress an
innate cellular antiviral activity (25). Whatever the
precise function of Vif turns out to be, the identification of the
residues involved in effector function will be critical to a full
appreciation of Vif's mechanism of action. A potential prediction for
such a domain is that its disruption would inhibit function but,
perhaps, not affect subcellular localization. Based on the results
presented here, the region spanning residues 114 to 146 may fulfill
these limited criteria. Specifically, all missense mutations in this
region either have full or substantial activity (M27, M11, M28, and
M12) or have essentially no activity but still localize to the
TX-100-insoluble fraction (M18, M19, M29, and
12). These results
should aid future structure-function analyses of HIV-1 Vif by providing
an initial framework of mutants that can be considered during the
design of more targeted mutagenesis studies.
In addition to examining the infectivity phenotypes of our various
mutant HIV-1 Vif proteins, we also tested them for potential dominant
negative behavior. However, despite numerous attempts, we failed to
identify any such mutant. Interestingly, a very recent report from
D'Aloja et al. described a variant of the HIV-1 vif gene
that does inhibit wild-type virus replication when expressed in
trans in either permissive or nonpermissive cells
(6). This mutated gene harbors ~14 amino acid changes with
respect to the Vif proteins of typical T-cell line-adapted isolates.
The future analysis of the mechanism of inhibition to replication by
this protein as well as its phenotype in the context of the assay
systems discussed here are of considerable interest.
 |
ACKNOWLEDGMENTS |
We thank Laurie Zimmerman for excellent secretarial support.
This work was supported by the Howard Hughes Medical Institute and
Public Health Service grant AI38715 from NIAID.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departments of
Microbiology and Medicine, University of Pennsylvania School of
Medicine, Clinical Research Bldg., Room 347B, 415 Curie Blvd.,
Philadelphia, PA 19104-6148. Phone: (215) 573-3493. Fax: (215)
573-2172. E-mail: malim{at}mail.med.upenn.edu.
 |
REFERENCES |
| 1.
|
Borman, A. M.,
C. Quillent,
P. Charneau,
C. Dauguet, and F. Clavel.
1995.
Human immunodeficiency virus type 1 Vif mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.
J. Virol.
69:2058-2067[Abstract].
|
| 2.
|
Bouyac, M.,
M. Courcoul,
G. Bertoia,
Y. Baudat,
D. Gabuzda,
D. Blanc,
N. Chazal,
P. Boulanger,
J. Sire,
R. Vigne, and B. Spire.
1997.
Human immunodeficiency virus type 1 Vif protein binds to the pr55Gag precursor.
J. Virol.
71:9358-9365[Abstract].
|
| 3.
|
Bouyac, M.,
F. Rey,
M. Nascimbeni,
M. Courcoul,
J. Sire,
D. Blanc,
F. Clavel,
R. Vigne, and B. Spire.
1997.
Phenotypically Vif human immunodeficiency virus type 1 is produced by chronically infected restrictive cells.
J. Virol.
71:2473-2477[Abstract].
|
| 4.
|
Camaur, D., and D. Trono.
1996.
Characterization of human immunodeficiency virus type 1 Vif particle incorporation.
J. Virol.
70:6106-6111[Abstract].
|
| 5.
|
Cullen, B. R.
1998.
HIV-1 auxiliary proteins: making connections in a dying cell.
Cell
93:685-692[Medline].
|
| 6.
|
D'Aloja, P.,
E. Olivetta,
R. Bona,
F. Nappi,
D. Pedacchia,
K. Pugliese,
G. Ferrari,
P. Verani, and M. Federico.
1998.
gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.
J. Virol.
72:4308-4319[Abstract/Free Full Text].
|
| 7.
|
Emerman, M., and M. H. Malim.
1998.
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.
Science
280:1880-1884[Abstract/Free Full Text].
|
| 8.
|
Fouchier, R. A. M.,
B. E. Meyer,
J. H. M. Simon,
U. Fischer, and M. H. Malim.
1997.
HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.
EMBO J.
16:4531-4539[Medline].
|
| 9.
|
Fouchier, R. A. M.,
J. H. M. Simon,
A. B. Jaffe, and M. H. Malim.
1996.
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins.
J. Virol.
70:8263-8269[Abstract].
|
| 10.
|
Gabuzda, D. H.,
K. Lawrence,
E. Langhoff,
E. Terwilliger,
T. Dorfman,
W. A. Haseltine, and J. Sodroski.
1992.
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.
J. Virol.
66:6489-6495[Abstract/Free Full Text].
|
| 11.
|
Goncalves, J.,
P. Jallepalli, and D. H. Gabuzda.
1994.
Subcellular localization of the Vif protein of human immunodeficiency virus type 1.
J. Virol.
68:704-712[Abstract/Free Full Text].
|
| 12.
|
Goncalves, J.,
Y. Korin,
J. Zack, and D. Gabuzda.
1996.
Role of Vif in human immunodeficiency virus type 1 reverse transcription.
J. Virol.
70:8701-8709[Abstract].
|
| 13.
|
Goncalves, J.,
B. Shi,
X. Yang, and D. Gabuzda.
1995.
Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.
J. Virol.
69:7196-7204[Abstract].
|
| 14.
|
Karczewski, M. K., and K. Strebel.
1996.
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.
J. Virol.
70:494-507[Abstract].
|
| 15.
|
Liu, H.,
X. Wu,
M. Newman,
G. M. Shaw,
B. H. Hahn, and J. C. Kappes.
1995.
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.
J. Virol.
69:7630-7638[Abstract].
|
| 16.
|
Ma, X.-Y.,
P. Sova,
W. Chao, and D. J. Volsky.
1994.
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.
J. Virol.
68:1714-1720[Abstract/Free Full Text].
|
| 17.
|
Malim, M. H.,
S. Böhnlein,
J. Hauber, and B. R. Cullen.
1989.
Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function.
Cell
58:205-214[Medline].
|
| 18.
|
Oberste, M. S., and M. A. Gonda.
1992.
Conservation of amino-acid sequence motifs in lentivirus Vif proteins.
Virus Genes
6:95-102[Medline].
|
| 19.
|
Ochsenbauer, C.,
V. Bosch,
I. Oelze, and U. Wieland.
1996.
Unimpaired function of a naturally occurring C terminally truncated vif gene product of human immunodeficiency virus type 1.
J. Gen. Virol.
77:1389-1395[Abstract/Free Full Text].
|
| 20.
|
Ochsenbauer, C.,
T. Wilk, and V. Bosch.
1997.
Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in `non-permissive' T lymphoid cells stably infected with selectable HIV-1.
J. Gen. Virol.
78:627-635[Abstract].
|
| 21.
|
Pearson, L.,
J. Garcia,
F. Wu,
N. Modesti,
J. Nelson, and R. Gaynor.
1990.
A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
Proc. Natl. Acad. Sci. USA
87:5079-5083[Abstract/Free Full Text].
|
| 22.
|
Sakai, H.,
R. Shibata,
J.-I. Sakuragi,
S. Sakuragi,
M. Kawamura, and A. Adachi.
1993.
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles.
J. Virol.
67:1663-1666[Abstract/Free Full Text].
|
| 23.
|
Simon, J. H. M.,
E. A. Carpenter,
R. A. M. Fouchier, and M. H. Malim.
1999.
Vif and the p55Gag polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes.
J. Virol.
73:2667-2674[Abstract/Free Full Text].
|
| 24.
|
Simon, J. H. M.,
R. A. M. Fouchier,
T. E. Southerling,
C. B. Guerra,
C. K. Grant, and M. H. Malim.
1997.
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells.
J. Virol.
71:5259-5267[Abstract].
|
| 25.
|
Simon, J. H. M.,
N. C. Gaddis,
R. A. M. Fouchier, and M. H. Malim.
1998.
Evidence for a newly discovered cellular anti-HIV-1 phenotype.
Nat. Med.
4:1397-1400[Medline].
|
| 26.
|
Simon, J. H. M., and M. H. Malim.
1996.
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.
J. Virol.
70:5297-5305[Abstract/Free Full Text].
|
| 27.
|
Simon, J. H. M.,
D. L. Miller,
R. A. M. Fouchier, and M. H. Malim.
1998.
Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function.
Virology
248:182-187[Medline].
|
| 28.
|
Simon, J. H. M.,
D. L. Miller,
R. A. M. Fouchier,
M. A. Soares,
K. W. C. Peden, and M. H. Malim.
1998.
The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission.
EMBO J.
17:1259-1267[Medline].
|
| 29.
|
Simon, J. H. M.,
T. E. Southerling,
J. C. Peterson,
B. E. Meyer, and M. H. Malim.
1995.
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.
J. Virol.
69:4166-4172[Abstract].
|
| 30.
|
Sudol, M.
1996.
The WW module competes with the SH3 domain?
Trends Biochem. Sci.
21:161-163[Medline].
|
| 31.
|
von Schwedler, U.,
J. Song,
C. Aiken, and D. Trono.
1993.
vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.
J. Virol.
67:4945-4955[Abstract/Free Full Text].
|
| 32.
|
Wieland, U.,
J. Hartmann,
H. Suhr,
B. Salzberger,
H. J. Eggers, and J. E. Kühn.
1994.
In vivo genetic variability of the HIV-1 vif gene.
Virology
203:43-51[Medline].
|
| 33.
|
Yang, X.,
J. Gonclaves, and D. Gabuzda.
1996.
Phosphorylation of Vif and its role in HIV-1 replication.
J. Biol. Chem.
271:10121-10129[Abstract/Free Full Text].
|
Journal of Virology, April 1999, p. 2675-2681, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mehle, A., Wilson, H., Zhang, C., Brazier, A. J., McPike, M., Pery, E., Gabuzda, D.
(2007). Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding. J. Virol.
81: 13235-13241
[Abstract]
[Full Text]
-
Russell, R. A., Pathak, V. K.
(2007). Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F. J. Virol.
81: 8201-8210
[Abstract]
[Full Text]
-
Paul, I., Cui, J., Maynard, E. L.
(2006). Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. USA
103: 18475-18480
[Abstract]
[Full Text]
-
Kobayashi, M., Takaori-Kondo, A., Miyauchi, Y., Iwai, K., Uchiyama, T.
(2005). Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C Complex Is Essential for Vif Function. J. Biol. Chem.
280: 18573-18578
[Abstract]
[Full Text]
-
Wichroski, M. J., Ichiyama, K., Rana, T. M.
(2005). Analysis of HIV-1 Viral Infectivity Factor-mediated Proteasome-dependent Depletion of APOBEC3G: CORRELATING FUNCTION AND SUBCELLULAR LOCALIZATION. J. Biol. Chem.
280: 8387-8396
[Abstract]
[Full Text]
-
Ribeiro, A. C., Maia e Silva, A., Santa-Marta, M., Pombo, A., Moniz-Pereira, J., Goncalves, J., Barahona, I.
(2005). Functional Analysis of Vif Protein Shows Less Restriction of Human Immunodeficiency Virus Type 2 by APOBEC3G. J. Virol.
79: 823-833
[Abstract]
[Full Text]
-
Kobayashi, M., Takaori-Kondo, A., Shindo, K., Abudu, A., Fukunaga, K., Uchiyama, T.
(2004). APOBEC3G Targets Specific Virus Species. J. Virol.
78: 8238-8244
[Abstract]
[Full Text]
-
Shindo, K., Takaori-Kondo, A., Kobayashi, M., Abudu, A., Fukunaga, K., Uchiyama, T.
(2003). The Enzymatic Activity of CEM15/Apobec-3G Is Essential for the Regulation of the Infectivity of HIV-1 Virion but Not a Sole Determinant of Its Antiviral Activity. J. Biol. Chem.
278: 44412-44416
[Abstract]
[Full Text]
-
Kao, S., Khan, M. A., Miyagi, E., Plishka, R., Buckler-White, A., Strebel, K.
(2003). The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity. J. Virol.
77: 11398-11407
[Abstract]
[Full Text]
-
Santiago, M. L., Bibollet-Ruche, F., Bailes, E., Kamenya, S., Muller, M. N., Lukasik, M., Pusey, A. E., Collins, D. A., Wrangham, R. W., Goodall, J., Shaw, G. M., Sharp, P. M., Hahn, B. H.
(2003). Amplification of a Complete Simian Immunodeficiency Virus Genome from Fecal RNA of a Wild Chimpanzee. J. Virol.
77: 2233-2242
[Abstract]
[Full Text]
-
Fujita, M., Sakurai, A., Yoshida, A., Miyaura, M., Koyama, A. H., Sakai, K., Adachi, A.
(2002). Amino Acid Residues 88 and 89 in the Central Hydrophilic Region of Human Immunodeficiency Virus Type 1 Vif Are Critical for Viral Infectivity by Enhancing the Steady-State Expression of Vif. J. Virol.
77: 1626-1632
[Abstract]
[Full Text]
-
Madani, N., Millette, R., Platt, E. J., Marin, M., Kozak, S. L., Bloch, D. B., Kabat, D.
(2002). Implication of the Lymphocyte-Specific Nuclear Body Protein Sp140 in an Innate Response to Human Immunodeficiency Virus Type 1. J. Virol.
76: 11133-11138
[Abstract]
[Full Text]
-
Khan, M. A., Akari, H., Kao, S., Aberham, C., Davis, D., Buckler-White, A., Strebel, K.
(2002). Intravirion Processing of the Human Immunodeficiency Virus Type 1 Vif Protein by the Viral Protease May Be Correlated with Vif Function. J. Virol.
76: 9112-9123
[Abstract]
[Full Text]
-
Altfeld, M., Addo, M. M., Eldridge, R. L., Yu, X. G., Thomas, S., Khatri, A., Strick, D., Phillips, M. N., Cohen, G. B., Islam, S. A., Kalams, S. A., Brander, C., Goulder, P. J. R., Rosenberg, E. S., Walker, B. D.
(2001). Vpr Is Preferentially Targeted by CTL During HIV-1 Infection. J. Immunol.
167: 2743-2752
[Abstract]
[Full Text]
-
Yang, S., Sun, Y., Zhang, H.
(2001). The Multimerization of Human Immunodeficiency Virus Type I Vif Protein. A REQUIREMENT FOR Vif FUNCTION IN THE VIRAL LIFE CYCLE. J. Biol. Chem.
276: 4889-4893
[Abstract]
[Full Text]
-
Hassaine, G., Courcoul, M., Bessou, G., Barthalay, Y., Picard, C., Olive, D., Collette, Y., Vigne, R., Decroly, E.
(2001). The Tyrosine Kinase Hck Is an Inhibitor of HIV-1 Replication Counteracted by the Viral Vif Protein. J. Biol. Chem.
276: 16885-16893
[Abstract]
[Full Text]